Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 67

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 67
---
-pesticides program against fruit rots, in October 2022, Lavie Bio announced the submission to the EPA of a registration package for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. In July 2023, Lavie Bio announced the signing of a licensing agreement with Corteva, as detailed below. In November 2024, Lavie Bio announced that Corteva decided to terminate the licensing agreement and Lavie Bio regained full rights and freedom to operate to the licensed technology and the lead bio-fungicide candidates.
 
On November 8, 2023, Lavie Bio reported significant progress with its bio-fungicide LAV321. In 2023, Lavie Bio achieved positive results in a series of field trials conducted across Europe and the United States, focusing on assessing LAV321’s efficacy in safeguarding crops against downy mildew and late blight diseases. Trials conducted across Europe achieved an average efficacy rate of ~55-60% against downy mildew in grapes. At Cornell University in New York, LAV321 demonstrated remarkable field trial results with a 97% efficacy rate against leaf disease and 53% against bunch disease. On November 19, 2024, Lavie Bio reported the advancement of LAV321 to Pre-Commercial stage, following successful field trials in Europe against downy mildew, reaching an average efficacy rate of 70%, and exceeding an average efficacy rate of 60% protecting tomato against late blight. These findings establish LAV321 as a potentially potent solution against fungal diseases, focusing on oomycetes class diseases, including downy mildew, late blight, and other blight diseases, all known for their destructive impact on crop yields.
 
With respect to Lavie Bio’s bio-stimulant programs for foliar application in soybean and cotton, on July 17, 2024, Lavie Bio and ICL reported significant advancement in the development of yield increasing bio-stimulants, identifying more than a dozen novel microbial candidates believed to have commercial viability as bio-stimulants for crops grown under extreme weather conditions, including drought, achieved within its first months of collaboration and leading to successful field trials in the U.S. in during 2024.
 
Key Collaborations
 
Corteva (originally with DuPont-Pioneer)
 
In July 2017, Evogene entered a multiyear collaboration with DuPont-Pioneer (now Corteva), for the research and